Investors should have expected Novavax’s (NASDAQ:NVAX) plunge in recent weeks. The stock failed to sustain the $200 – $300 level in 2021. And as the leaders continue to increase vaccine sales, Novavax’s lack of product to market is disconcerting.
Moderna (NASDAQ:MRNA) is exhibiting a “double top” bearish signal on the stock chart. At $180, the stock failed to break out above that around three times. MRNA stock is the best COVID-19 vaccine stock today. It has strong prospects in developing vaccines for other viruses. Plus, its cancer pipeline is promising.
BioNTech SE (NASDAQ:BNTX), in partnership with Pfizer (NYSE:PFE), is paying off. Both stocks are good picks for investors seeking exposure to the vaccine market. BNTX stock valuations are still high. But as the market realizes BioNTech taking more market share in a growing addressable market, the stock will not look so expensive.
Inovio (NASDAQ:INO) is not investable. The company failed to bring a product to market soon enough. Conversely, the single-dose vaccine from Johnson & Johnson (NYSE:JNJ) is promising. Both PFE and JNJ stock offer dividend income investors some long-term stability. Those investors may also continue holding BNTX and MRNA stock for the long-term capital upside.